Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-Escalation of Busulfan in HSCT for SCID
NCT00228852Phase 2Completed
- Sponsor
- Emory University
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan in severe combined immunodeficiency (SCID), T-cell immunodeficiency, sponsored by Emory University. Status: completed.
02
Drugs
busulfan
03
Conditions
severe combined immunodeficiency (SCID)T-cell immunodeficiency
Beyond the preview
Go deeper on NCT00228852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228852.